GPT and metabolic dysfunction-associated steatotic liver disease: Since it is hard to get the liver tissues from NAFLD patients, most of the clinical trials used serological markers (e.g., serum ALT, AST, TG, TC, HDL, LDL, FFA, glucose, and insulin levels) for the primary outcomes.